Reglan Tardive Dyskinesia Settlement: Claim Valuation Factors Overview

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Occupational Risk

For decades, general health and science information has served as the foundation for public understanding of medication risks and benefits. This broad educational context has empowered individuals to make informed decisions about treatments ranging from common antibiotics to complex therapeutic regimens. Within this legacy framework, the emphasis has been on balancing therapeutic efficacy against potential adverse effects, with particular attention to neurological and movement-related complications that may arise from long-term medication use. As we pivot from this general health perspective to a more focused occupational exposure concern, it becomes essential to consider how certain medications—prescribed in routine clinical settings—can lead to unintended consequences that affect daily functioning and quality of life. One such medication is Reglan (metoclopramide), commonly used for gastrointestinal motility disorders. Prolonged use of Reglan has been associated with an increased risk of developing tardive dyskinesia, a condition characterized by involuntary, repetitive movements. For individuals in mass production environments, where fine motor control and coordination are critical, the onset of such movement disorders can have profound implications for workplace safety, productivity, and long-term employability. This transition from general health awareness to specific occupational risk underscores the need for careful consideration of medication exposure in the context of job demands and legal recourse.

Find Out If You Qualify for Compensation →

Understanding Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is associated with tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA-approved labeling for Reglan includes a boxed warning stating that metoclopramide can cause TD, and the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning further notes that Reglan is contraindicated in patients with a history of TD, and that the drug should be used for the shortest duration necessary, with periodic reassessment of continued need. For patients with symptomatic, documented gastroesophageal reflux, the maximum treatment duration is 12 weeks. In diabetic gastroparesis, total treatment with metoclopramide products, including Reglan tablets, should not exceed 12 weeks; if longer use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The clinical presentation of TD involves involuntary, repetitive movements, often of the face or tongue, and may also affect the trunk and extremities. The labeling describes TD as a syndrome of potentially irreversible and disfiguring movements, and notes that metoclopramide may suppress or partially suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Diagnosis is based on clinical evaluation, including history of exposure to dopamine-blocking agents like metoclopramide, and observation of characteristic movements.

Epidemiological Evidence and Risk Factors

Epidemiological data on the incidence of metoclopramide-induced TD have varied. A real-world epidemiology study using the MarketScan Research database (2011-2020) analyzed TD incidence in adults with at least 12 months of medical and pharmacy benefits, comparing rates among metoclopramide-treated gastroparesis patients, untreated patients, and the general population (https://pubmed.ncbi.nlm.nih.gov/41588797/). This study aimed to reassess TD risk given inconsistent estimates from older studies, which ranged from 1% to 15%. Another review of the literature, including PubMed and Google Scholar searches, reported that the risk of TD from metoclopramide is low, approximately 0.1% per 1000 patient-years, which is far below the previously estimated 1%-10% risk suggested in treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). This review identified high-risk groups as elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications. The mechanistic pathway linking metoclopramide to TD involves dopamine receptor blockade in the basal ganglia. Metoclopramide is a dopamine D2 receptor antagonist, and chronic blockade can lead to upregulation of dopamine receptors, resulting in hypersensitivity and abnormal involuntary movements. The FDA labeling warns against concomitant use of other drugs known to cause TD, extrapyramidal symptoms (EPS), or neuroleptic malignant syndrome (NMS), and advises avoidance in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If symptoms occur, immediate discontinuation of Reglan and medical attention are recommended.

Claim Valuation Factors in Reglan TD Settlements

From a risk perspective, the adequacy of warnings regarding Reglan and TD is addressed by the boxed warning, which is the strongest FDA-required warning. However, historical concerns about under-recognition of TD risk have led to litigation. Settlement-related considerations for affected patients typically involve factors such as the duration and dosage of Reglan exposure, the severity and irreversibility of TD symptoms, the presence of high-risk factors (e.g., elderly, diabetic, renal/hepatic impairment), and the timeline between exposure and documented harm. The boxed warning emphasizes that the risk increases with treatment duration and cumulative dosage, and that the maximum treatment duration for approved indications is 12 weeks. Patients who developed TD after prolonged use beyond this period may have stronger claims regarding inadequate monitoring or failure to discontinue therapy. The timeline between exposure and harm is critical. TD can develop after months or years of metoclopramide use, and symptoms may persist or become permanent even after drug discontinuation. The labeling advises immediate discontinuation if signs or symptoms of TD occur, but notes that metoclopramide may mask the underlying disease process, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In settlement contexts, the duration of exposure, cumulative dose, and time to symptom onset are key factors in valuing claims. In summary, Reglan-associated TD is a serious adverse effect with a well-documented pharmacological basis. While the absolute risk may be lower than earlier estimates, high-risk populations require careful monitoring. The FDA boxed warning provides clear guidance on limiting treatment duration and contraindications, but adherence to these recommendations in clinical practice has been variable, contributing to litigation and settlement considerations.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Reglan and how is it linked to tardive dyskinesia?

Reglan (metoclopramide) is a medication used for gastrointestinal motility disorders. It is associated with tardive dyskinesia (TD), a potentially irreversible movement disorder, as indicated by an FDA boxed warning. The risk increases with duration of treatment and cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What factors are considered in valuing a Reglan TD claim?

Key factors include duration and dosage of Reglan exposure, severity and irreversibility of TD symptoms, presence of high-risk factors (e.g., elderly, diabetic, renal/hepatic impairment), and the timeline between exposure and documented harm. The FDA boxed warning emphasizes limiting treatment to 12 weeks, and prolonged use may strengthen claims (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.